{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T03:30:06Z","timestamp":1786332606966,"version":"build-2736575974"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases of the National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI136979"],"award-info":[{"award-number":["R01AI136979"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>We have shown that dalbavancin exposure can select for mutants with reduced susceptibilities to vancomycin and daptomycin, and several clinical cases of such resistance have been documented. Synergistic antimicrobial combinations may reduce resistance selection and enhance the activity of dalbavancin for deep-seated infections. Since the key advantage of dalbavancin is its infrequent dosing, the objective of this study was to evaluate whether orally bioavailable antibiotics typically dosed \u2264 twice daily were synergistic with dalbavancin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using five isogenic S. aureus strain pairs (susceptible parent strain and a dalbavancin-selected resistant strain), we assessed for synergy between dalbavancin and cefadroxil, trimethoprim, doxycycline, moxifloxacin, and clarithromycin by standard time-kill methods.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Cefadroxil was synergistic with dalbavancin against every strain tested. When combined with dalbavancin, trimethoprim was synergistic against 6\/8 trimethoprim-susceptible strains, moxifloxacin was synergistic against 6\/10 strains, doxycycline was synergistic against 2 strains but antagonistic against 2 strains, and clarithromycin was synergistic against 2\/6 clarithromycin-susceptible strains. All other interactions were indifferent.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Cefadroxil is a first-generation cephalosporin, like cephalexin, but with a longer half-life that allows for a typical 12-h dosing interval. In our study, we found that synergy between cefadroxil and dalbavancin was common regardless of susceptibility to cefadroxil or dalbavancin, suggesting that this might be a promising companion agent to add to dalbavancin in patients with deep-seated infections that may benefit from synergistic activity to enhance bactericidal effects. Trimethoprim\/sulfamethoxazole and moxifloxacin may improve activity and are unlikely to be antagonistic. Clarithromycin and doxycycline seem least likely to offer a benefit.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkag264","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T12:07:30Z","timestamp":1784722050000},"source":"Crossref","is-referenced-by-count":0,"title":["Synergy between orally bioavailable antibiotics and dalbavancin against MRSA"],"prefix":"10.1093","volume":"81","author":[{"given":"Ethan","family":"Ahrendt","sequence":"first","affiliation":[{"name":"Department of Pharmacy, School of Pharmacy, University of Washington , 1959 NE Pacific St., HSB H-375, BOX 357630, Seattle, WA 98195-7630 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie C L","family":"Foreman","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, School of Pharmacy, University of Washington , 1959 NE Pacific St., HSB H-375, BOX 357630, Seattle, WA 98195-7630 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6751-4098","authenticated-orcid":false,"given":"Brian J","family":"Werth","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, School of Pharmacy, University of Washington , 1959 NE Pacific St., HSB H-375, BOX 357630, Seattle, WA 98195-7630 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,10]]},"reference":[{"key":"2026080923170542700_dkag264-B1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofag074","article-title":"Emergence of dalbavancin, vancomycin, and daptomycin cross-resistance in MRSA during long-term LVAD suppression with vancomycin followed by dalbavancin: genomic insights and synergy with cefadroxil","volume":"13","author":"Stohs","year":"2026","journal-title":"Open Forum Infect Dis"},{"key":"2026080923170542700_dkag264-B2","doi-asserted-by":"publisher","first-page":"910.e1","DOI":"10.1016\/j.cmi.2020.08.025","article-title":"Dalbavancin exposure in vitro selects for dalbavancin-non-susceptible and vancomycin-intermediate strains of methicillin-resistant Staphylococcus aureus","volume":"27","author":"Werth","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"2026080923170542700_dkag264-B3","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1093\/cid\/ciac341","article-title":"Emergence of dalbavancin, vancomycin, and daptomycin non-susceptible Staphylococcus aureus in a patient treated with dalbavancin: case report and isolate characterization","volume":"75","author":"Zhang","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2026080923170542700_dkag264-B4","doi-asserted-by":"publisher","first-page":"429.e1","DOI":"10.1016\/j.cmi.2017.07.028","article-title":"Emergence of dalbavancin non-susceptible, vancomycin-intermediate Staphylococcus aureus (VISA) after treatment of MRSA central line-associated bloodstream infection with a dalbavancin- and vancomycin-containing regimen","volume":"24","author":"Werth","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"2026080923170542700_dkag264-B5","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1093\/jac\/dkz562","article-title":"Occurrence of cross-resistance and beta-lactam seesaw effect in glycopeptide-, lipopeptide- and lipoglycopeptide-resistant MRSA correlates with membrane phosphatidylglycerol levels","volume":"75","author":"Hines","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2026080923170542700_dkag264-B6","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2021.688357","article-title":"Synergy between Beta-lactams and lipo-, glyco-, and lipoglycopeptides, is independent of the seesaw effect in Methicillin-Resistant Staphylococcus aureus","volume":"8","author":"Zhang","year":"2021","journal-title":"Front Mol Biosci"},{"key":"2026080923170542700_dkag264-B7","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01743-18","article-title":"Dalbavancin alone and in combination with ceftaroline against four different phenotypes of Staphylococcus aureus in a simulated pharmacodynamic\/pharmacokinetic model","volume":"63","author":"Kebriaei","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2026080923170542700_dkag264-B8","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1093\/jac\/dky376","article-title":"Evaluation of dalbavancin alone and in combination with beta-lactam antibiotics against resistant phenotypes of Staphylococcus aureus","volume":"74","author":"Xhemali","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2026080923170542700_dkag264-B9","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41426-018-0205-z","article-title":"Emergence of a dalbavancin induced glycopeptide\/lipoglycopeptide non-susceptible Staphylococcus aureus during treatment of a cardiac device-related endocarditis","volume":"7","author":"Kussmann","year":"2018","journal-title":"Emerg Microbes Infect"},{"key":"2026080923170542700_dkag264-B10","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/jcpt.12580","article-title":"Unsuccessful treatment of methicillin-resistant Staphylococcus aureus endocarditis with dalbavancin","volume":"43","author":"Steele","year":"2018","journal-title":"J Clin Pharm Ther"},{"key":"2026080923170542700_dkag264-B11","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1093\/cid\/ciy279","article-title":"Dalbavancin as primary and sequential treatment for gram-positive infective endocarditis: 2-year experience at the General Hospital of Vienna","volume":"67","author":"Tobudic","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2026080923170542700_dkag264-B12","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1001\/jama.2025.12543","article-title":"Dalbavancin for treatment of Staphylococcus aureus bacteremia: the DOTS randomized clinical trial","volume":"334","author":"Turner","year":"2025","journal-title":"JAMA"},{"key":"2026080923170542700_dkag264-B13","doi-asserted-by":"publisher","first-page":"15515","DOI":"10.1038\/s41598-025-99112-7","article-title":"Exploratory analysis of long-term suppressive therapy with dalbavancin in ventricular assist device infections caused by Staphylococcus aureus","volume":"15","author":"Morath","year":"2025","journal-title":"Sci Rep"},{"key":"2026080923170542700_dkag264-B14","doi-asserted-by":"publisher","first-page":"189","DOI":"10.3390\/pathogens13030189","article-title":"New frontier on antimicrobial therapy: long-acting lipoglycopeptides","volume":"13","author":"Siciliano","year":"2024","journal-title":"Pathogens"},{"key":"2026080923170542700_dkag264-B15","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jmsacl.2023.12.003","article-title":"Therapeutic drug monitoring of glycopeptide antimicrobials: an overview of liquid chromatography-tandem mass spectrometry methods","volume":"31","author":"Cafaro","year":"2024","journal-title":"J Mass Spectrom Adv Clin Lab"},{"key":"2026080923170542700_dkag264-B16","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1185602","article-title":"Dalbavancin as suppressive antibiotic therapy in patients with prosthetic infections: efficacy and safety","volume":"14","author":"Ruiz-Sancho","year":"2023","journal-title":"Front Pharmacol"},{"key":"2026080923170542700_dkag264-B17","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad537","article-title":"Long-term dalbavancin for suppression of gram-positive chronic left ventricular assist device infections","volume":"10","author":"Rowe","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"2026080923170542700_dkag264-B18","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1080\/1120009X.2022.2136426","article-title":"Dalbavancin as chronic antibiotic suppression therapy for left ventricular assist device driveline infection due to methicillin-resistant Staphylococcus aureus: a case report","volume":"35","author":"Pallotto","year":"2023","journal-title":"J Chemother"},{"key":"2026080923170542700_dkag264-B19","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01092-25","article-title":"Monthly dalbavancin dosing for suppressive therapy: a pharmacokinetic estimation analysis and case series","volume":"70","author":"Kufel","year":"2026","journal-title":"Antimicrob Agents Chemother"},{"key":"2026080923170542700_dkag264-B20","doi-asserted-by":"publisher","first-page":"696","DOI":"10.3390\/antibiotics9100696","article-title":"Dalbavancin, vancomycin and daptomycin alone and in combination with cefazolin against resistant phenotypes of Staphylococcus aureus in a pharmacokinetic\/pharmacodynamic model","volume":"9","author":"Abdul-Mutakabbir","year":"2020","journal-title":"Antibiotics"},{"key":"2026080923170542700_dkag264-B21","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1001\/archinte.1951.03810100073006","article-title":"Treatment of pneumococcic meningitis with penicillin compared with penicillin plus aureomycin: studies including observations on an apparent antagonism between penicillin and aureomycin","volume":"88","author":"Lepper","year":"1951","journal-title":"AMA Arch Intern Med"},{"key":"2026080923170542700_dkag264-B22","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1038\/s41467-020-15966-7","article-title":"Intracellular Staphylococcus aureus persisters upon antibiotic exposure","volume":"11","author":"Peyrusson","year":"2020","journal-title":"Nat Commun"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/9\/dkag264\/70581227\/dkag264.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/9\/dkag264\/70581227\/dkag264.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T03:17:15Z","timestamp":1786331835000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/doi\/10.1093\/jac\/dkag264\/8757709"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,8,4]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkag264","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,8,4]]},"article-number":"dkag264"}}